COPD
Once-Daily Nebulized Therapy for COPD Gets FDA Approval
Once-Daily Nebulized Therapy for COPD Gets FDA Approval
Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.
 
Read More >>
Inhalation Spray Label Revised to Include New Data, Broader Indication
Psychological Distress and Socioeconomic Status Increase Risk for Chronic Diseases
FDA Approves Treatment Device for Severe Emphysema
Study Suggests an Increase in Monitoring Needed For Patients With Asthma, COPD
COPD Management Strategies and Minimizing Medication Waste in the Hospital Setting
New Digital Platform is Increasing Inhaler Adherence
COPD: Causes, Stages, and Treatments
View more articles >>
Clinical Trials
Impact of Vitamin D3 Administration on Cardiac Autonomic Tone in Asthma Chronic Obstructive Pulmonary Disease(COPD) Overlap Patients
Determinants of the Vascular Response to Training in Chronic Obstructive Pulmonary Disease (COPD) Patients
Heated High Humidity After COPD Exacerbation
Structured Comprehensive Intervention to Stimulate Self- Management and Improve Quality of Life in COPD Patients
Shared Decision Making in Hospitalized AECOPD
Multimedia: Videos
How to Improve Patient Adherence to Long-Term Asthma and COPD Treatment
How to Improve Patient Adherence to Long-Term Asthma and COPD Treatment
How Pharmacists Can Help Patients Remember Which Medication Is Used for Which Problem
How Pharmacists Can Help Patients Remember Which Medication Is Used for Which Problem
Counseling Points Pharmacists Should Make When Demonstrating Proper Inhaler Use
Counseling Points Pharmacists Should Make When Demonstrating Proper Inhaler Use
How Technology Is Changing the Inhaler Industry
How Technology Is Changing the Inhaler Industry